Feedback
Drugs of Abuse 9A Panel, Urine - Screen Only
0090454
Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. For follow-up testing of a presumptive result, confirmatory testing by mass spectrometry is recommended. For automatic reflex testing on all presumptive positives, Drug Panel 9A, Urine - Screen with Reflex to Confirmation/Quantitation (0092187) is recommended.

Mnemonic
CDTI9A
Methodology
Qualitative Enzyme Multiplied Immunoassay Technique/Alcohol Dehydrogenase
Performed
Sun-Sat
Reported
1-2 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Random urine. 
Specimen Preparation
Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Specimens exposed to repeated freeze/thaw cycles. 
Remarks
 
Stability
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years 
Reference Interval
Effective August 17, 2015
Drugs Covered and Cutoff Concentrations
Drugs
Screen
THC (Cannabinoids)20 ng/mL
Cocaine150 ng/mL
Opiates300 ng/mL
Oxycodone100 ng/mL
Phencyclidine25 ng/mL
Amphetamines300 ng/mL
MDMA (Ecstasy)500 ng/mL
Barbiturates200 ng/mL
Benzodiazepines200 ng/mL
Methadone150 ng/mL
Propoxyphene300 ng/mL
Alcohol40 mg/dL

Interpretive Data
This is a screening test only. False positive and false negative results can occur. Positive results are not automatically reflexed to a confirmatory test Confirmation by GC/MS and/or LC-MS/MS must be requested separately. Confirmatory testing for drugs and/or drug classes detected by this screening test is recommended.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

The following opioids are not detected in this test, but can be ordered separately: fentanyl, buprenorphine, meperidine, tramadol, and tapentadol. A comprehensive panel that includes these opioids is available or individual opioid testing can be ordered. Refer to aruplab.com for test information.

For medical purposes only; not valid for forensic use.

Note
To order testing for individual opioids, refer to Fentanyl and Metabolite - Confirmation/Quantitation - Urine (ARUP test code 0092570), Buprenorphine and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2010092), Meperidine and Metabolite - Confirmation/Quantitation - Urine (ARUP test code 2002760), Tramadol and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2002736). For the comprehensive panel, refer to Pain Management Drug Panel by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine (ARUP test code 2007479).
CPT Code(s)
80307
Components
Component Test Code*Component Chart NameLOINC
0090381Amphetamines, Urn, Screen3349-8
0090382Barbiturates, Urn, Screen3377-9
0090383Benzodiazepines, Urn, Screen3390-2
0090386Creatinine, Urine2161-8
0090387Propoxyphene, Urn, Screen19141-1
0090388Cocaine, Urn, Screen3397-7
0090389Methadone, Urn, Screen3773-9
0090396Opiates, Urn, Screen3879-4
0090397Phencyclidine, Urn, Screen19659-2
0090398THC, Urn, Screen18282-4
0090419Drug Panel 9A, Screen Only - Comments
0090488Alcohol, Urn, Screen5644-0
2004776Oxycodone, Urn, Screen19644-4
2004778MDMA, Urn, Screen19571-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Dolophine
  • Pain Management